Pharmaceuticals
Viatris Q2 FY2026 revenue rose 5% but operating income plunged 97% due to a $178M product rights impairment, resulting in a net loss of $118.8M.
Key risk: Severe Operating Income Decline
Operating income dropped 97.3% to $6.3 million as SG&A rose 22.2% to $1.13 billion, largely due to a $177.8 million impairment on product rights, raising concerns about expense management and asset value.
Other Pharmaceuticals companies